Trading of Active Pharmaceutical Ingredients

The Active Pharmaceutical Ingredients (APIs) trading business was our first business as a company, and still stands today to service local manufacturers in Spain and Portugal with API solutions from leading manufacturers. 

We will be happy to meet your API sourcing needs whatever the product, territory or collaboration model.


Established partnerships with leading API suppliers

We have secured exclusive distribution agreements with leading manufacturers for Spain and Portugal. Our knowledge on the API field is extensive and our contacts are countless. Our distribution operations go back to our origins as a company and are the foundations of our current position in the API distribution business but also in the development of pharmaceutical products. 


In search of our customers’ needs

End-to-end delivery of API products from our suppliers’ to our clients’ sites as well as the use of different logistic models per customer and product has proven a success and provides reliability to our customers. Our team has vast experience in dealing with suppliers from different countries, ensuring the best customer experience for our clients.

One of our favorite challenges is to help in the search of difficult API sourcing. Please contact us for any assistance; we would love to help you meet your API challenges.


Collaboration beyond distribution

At Galenicum Axium, any collaboration beyond distribution is also possible. If we can cover our customer needs, we are happy to go beyond the established distribution model and go the extra mile to reach our goals. As a proof, we have already experience in both:

  • DMF development and qualification of manufacturers for the regulated markets
  • Co-development agreement with API manufacturers for the API development

KEY figures


RESTRICTED ACCESS

The information contained in this section is aimed at the healthcare professional of the Pharmaceutical Industry, therefore, specialized training is required for its correct interpretation.

The products mentioned may have a different authorized data sheet in each country.

If you click the "accept" button, you are expressing your willingness to access the information explicitly intended for healthcare professionals.

DABIGAMAX

DEVELOPMENT OF THE FIRST GENERIC PHARMACEUTICAL SPECIALTY WITH DABIGATRAN. Decision EMC/2755/2017, dated November 20, (DOGC núm. 7508 of 30/11/2017) regarding the call for NUCLEUS OF INDUSTRIAL RESEARCH AND EXPERIMENTAL DEVELOPMENT (file number RD17-1-0006). This project has received funding from the European Union through the European Regional Development Fund (ERDF). With the collaboration from ACCIÓ.

POLÍTICA DE COOKIES

Nos preocupamos por su seguridad y privacidad cuando utiliza Internet. Nuestro sitio web no utiliza cookies para almacenar datos personales ni intercambiarlos con terceros. Sin embargo, este sitio web hace uso de cookies para mejorar la funcionalidad y el rendimiento y cookies de terceros. Si continúa la lectura y el uso de nuestro sitio web, usted está de acuerdo en el uso de las cookies.
Para más información, consulte nuestra política de cookies.